Tenderwize
Retour à la recherche

Medicinal product with olodaterol and tiotropium bromide (ATC: R03AL06)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Apr 29, 2027 · 243 days left·Open·Supplies
Titre original de l'avis

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Olodaterol und Tiotropiumbromid (ATC: R03AL06)

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No estimated contract value or budget is disclosed, so potential revenue cannot be assessed.

If the authority awards exclusive contracts during the term, the open-house contracts will be terminated.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Non-exclusive discount agreements for finished medicinal products containing olodaterol and tiotropium bromide (ATC: R03AL06)
  • Open-house model: any qualified pharmaceutical company can join at any time
Afficher le résumé complet

This is an open-house model for non-exclusive discount agreements under § 130a Abs. 8 SGB V for finished medicinal products containing the active substances olodaterol and tiotropium bromide (ATC: R03AL06). The contracting authority is AOK Sachsen-Anhalt. Any qualified pharmaceutical company can join at any time under standard terms. The contract runs from 1 July 2025 to 30 June 2027 (max 24 months). There is no estimated value provided. The procedure is not a public procurement under EU law despite using an open procedure notice form. Submission is via postal mail or electronically with qualified electronic signature. The deadline for submission is 30 April 2027, but the model allows participation at any time until that date.

Risques

No estimated contract value or budget is disclosed, so potential revenue cannot be assessed.

If the authority awards exclusive contracts during the term, the open-house contracts will be terminated.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company or a group of pharmaceutical companies

Administrative

  • Complete and sign the participation documents
  • Submit participation documents via postal mail or electronically with qualified electronic signature

Critères d'attribution

Lot 1

No award criteria defined; open to all qualifying companies.

Acheteur

Localisation

Magdeburg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE258393558

Activité

Health

Lots (1)

LOT-0001

Medicinal product with olodaterol and tiotropium bromide (ATC: R03AL06)

Non-exclusive discount agreements for finished medicinal products containing olodaterol and tiotropium bromide (ATC: R03AL06) under an open-house model. Any eligible pharmaceutical company can conclude a contract at any time. Contract duration maximum 24 months ending 30 June 2027. The contract may be terminated if the authority awards exclusive contracts later.

SuppliesEU fundedElectronic submission

Localisation

DEE03, Germany

Durée

2 YEAR

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria defined; open to all qualifying companies.

Date limite

Deadline Apr 29, 2027

Détails de la procédure

Date de publication
18 May 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
320165-2025

Documents (1)

Appels d'offres similaires